Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

Published:2020-01-22 Issue:2 Volume:11 Page:101-107
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Konteatis Zenon¹,Artin Erin¹,Nicolay Brandon¹,Straley Kimberly¹,Padyana Anil K.¹,Jin Lei¹,Chen Yue¹,Narayaraswamy Rohini¹,Tong Shuilong²,Wang Feng³,Zhou Ding⁴,Cui Dawei⁴,Cai Zhenwei⁴,Luo Zhiyong⁵,Fang Cheng⁵,Tang Huachun⁵,Lv Xiaobing⁵,Nagaraja Raj¹,Yang Hua¹,Su Shin-San M.¹,Sui Zhihua¹,Dang Lenny¹^ORCID,Yen Katharine¹,Popovici-Muller Janeta¹,Codega Paolo⁶,Campos Carl⁶,Mellinghoff Ingo K.⁶,Biller Scott A.¹

Affiliation:

1. Agios Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, United States

2. Viva Biotech, Shanghai 201203, China

3. Wuxi Biortus Biosciences Co. Ltd, Jiangyin 214437, China

4. PharmaResources, Shanghai 201201, China

5. ChemPartner, Shanghai 201203, China

6. Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States

Funder

Agios Pharmaceuticals, Inc.

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

http://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.9b00509

Reference20 articles.

1. IDH mutations in cancer and progress toward development of targeted therapeutics

2. IDH1andIDH2Mutations in Gliomas

3. The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

4. An Integrated Genomic Analysis of Human Glioblastoma Multiforme

5. Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biostructural, biochemical and biophysical studies of mutant IDH1;Nature Communications;2024-09-09

2. Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study;European Journal of Medicinal Chemistry;2024-09

3. Development of Machine Learning-based QSAR Models for the Designing of Novel Anti-cancer Therapeutics Against Malignant Glioma;2024-08-19

4. ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain;Fluids and Barriers of the CNS;2024-08-05

5. Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations;Bioorganic Chemistry;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3